Ilika plc Trading Update, Notice of Results & Presentations (5202U)

TIDMIKA

RNS Number : 5202U

Ilika plc

24 November 2023

Ilika plc

("Ilika", the "Group". or the "Company")

Trading Update & Notice of Half-Year Results

Analyst and Investor Presentations

Ilika (AIM: IKA), a pioneer in solid-state battery technology, provides an update on trading and notice of results for the six months ended 31 October 2023 (the "Period").

Operating Highlights:

Stereax (Ò)

In the first half of the current financial year Ilika continued to develop the scale and potential reach of its Stereax business. The Period started with shipments of stacked M300 batteries from its UK manufacturing facility - being the first of a series of planned deliveries to customers.

The licencing and royalty agreement with US-headquartered Cirtec Medical ("Cirtec"), which was signed in August 2023, was a key milestone for the Group, enabling the transfer of Stereax production to Cirtec's manufacturing facility in Lowell, MA.

Ilika has now completed the despatch of the key equipment required to manufacture Stereax batteries to Cirtec, with the exception of the cathode manufacturing process which will initially remain with Ilika in the UK. Cirtec is currently expanding its cleanroom capacity in Lowell to accommodate growth in its business, including Stereax manufacturing. Ilika and Cirtec continue to work closely with a portfolio of 20 customers to support their development plans and launch schedules.

Goliath Programme

Ilika's Goliath programme also progressed strongly during the Period - especially from the perspective of improving technical parameters and implementing its production scale-up plans. Based on the performance of recent prototypes, the Company confirmed the achievement of its D4 technical milestone and remains firmly on track to achieve lithium-ion energy density parity by the end of 2023, in-line with guidance set out in November 2022.

The development efforts are supported by the Faraday Battery Challenge 24-month, GBP8.2m grant-funded HISTORY project, steered with input from BMW and WAE (Williams Advanced Engineering), to integrate high silicon content electrodes into Goliath. In parallel, Ilika has been trialling production-intent equipment at vendor sites and its pilot facility in the UK. Since October 2023, this scale-up work has been supported by the Automotive Transformation Fund 16-month, GBP2.7m grant-supported SiSTEM project, in which Ilika is collaborating with Mpac plc and UK Battery Industrialisation Centre (UKBIC). Ilika continues to interact closely with many of the global automotive OEMs, with a view to sharing Goliath P1 prototypes for their evaluation in H1 CY 2024, as a precursor to large-scale manufacturing through licensing.

Financial Highlights:

The Company expects to announce revenue of GBP1.3m (H1 2023: GBP0.2m) as a result of increased grant funding received during the Period through the HISTORY programme and the newly announced SiSTEM grant. This positive income position is not expected to be mirrored in the second half of the financial year due to phasing of the grant activity. EBITDA loss, excluding share-based payments, of GBP1.9m (H1 2023: loss of GBP4.1m) for the six months ended 31 October 2023, reflects the higher income and cost reduction resulting from the technology transfer of Stereax production to Cirtec. Cash and cash equivalents at the period end were GBP13.2m (H1 2023: GBP18.6m).

Notice of Results:

Ilika expects to announce half-year results for the six months ended 31 October 2023 on Tuesday 23 January 2024.

Analyst Briefing

The management team will be hosting a hybrid analyst briefing on the day, 23 January 2024, at 9.30am. Analysts who wish to attend should contact Nick Rome at Walbrook PR on [phone] or email [e-mail] to register.

Investor Presentation

An investor presentation will be held on the day, 23 January 2023, at 4.30pm and will be hosted through the digital platform, Investor Meet Company. Investors can sign up to Investor Meet Company for free and add meet Ilika plc via the following link: https://www.investormeetcompany.com/ilika-plc/register-investor . For more information, please contact Walbrook PR at [e-mail] .

For more information contact:

 
 
 Ilika plc                                                  www.ilika.com 
 Graeme Purdy, Chief Executive                            Via Walbrook PR 
 
 
 
 Liberum Capital Limited (Nomad                        Tel: [phone] 
  and Joint Broker) 
 Andrew Godber, 
 Nikhil Varghese 
 
 
 Joh. Berenberg, Gossler & Co. KG                      Tel: [phone] 
  (Joint Broker) 
 Matthew Armitt, Mark Whitmore, Detlir 
  Elezi, 
 Natasha Ninkov 
 
 
 Walbrook PR Ltd                Tel: [phone] / [e-mail] 
 Nick Rome                                             Mob: [phone] 
 Charlotte Edgar                                       Mob: [phone] 
 Joe Walker                                            Mob: [phone] 
 
 

About Ilika plc - https://www.ilika.com .

Ilika specialises in the developing and commercialisation of solid state batteries. The Company's mission is to rapidly develop leading-edge IP, manufacture and license solid state batteries for markets that cannot be addressed with conventional batteries due to their safety, charge rates, energy density and life limits. The Company achieves this by using ceramic-based lithium-ion technology that is inherently safe in manufacture and usage, higher thermal tolerance and easier to recycle which differentiates our products from existing batteries.

The Company has two product lines. Its Stereax batteries which are designed for powering miniature medical implants, industrial wireless sensors and specialist internet of Things (IoT) applications and the Goliath large format batteries designed for EV cars and cordless appliances.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TSTPPGBAGUPWGQW

(END) Dow Jones Newswires

November 24, 2023 02:00 ET (07:00 GMT)